• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫特征可区分与 SARS-CoV-2 相关的重症疾病患者。

Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2.

机构信息

Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Department of Clinical laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

出版信息

Immunol Res. 2020 Dec;68(6):398-404. doi: 10.1007/s12026-020-09156-2. Epub 2020 Sep 28.

DOI:10.1007/s12026-020-09156-2
PMID:32989677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7521864/
Abstract

This single-center, retrospective study aimed to explore the immune characteristics of COVID-19 and biomarkers to predict the severity of this disease. Patients infected with SARS-CoV-2 (n = 215) treated at the First Affiliated Hospital of Nanchang University from January 24 to March 12, 2020, were included in the study and classified into severe and non-severe groups. Peripheral immunocyte count and cytokine statuses were compared. The correlation between immune status, cytokine levels, and disease severity was analyzed. Leukocyte numbers were normal in both groups; however, they were relatively high (7.19 × 10/L) in patients of the severe group. Leukocyte distributions differed between the two groups; the severe group had a higher percentage of neutrophils and lower percentage of lymphocytes compared with the non-severe group, and absolute lymphocyte numbers were below normal in both groups, and particularly deficient in patients in the severe group. Lymphocyte counts have negative correlation with duration of hospital period whereas neutrophil count has no significant correlation with it. Of tested cytokines, IL-6 levels were significantly higher in the severe group (P = 0.0418). Low level of lymphocyte predicts severity of COVID-19. IL-6 levels were significantly higher in the severe group, especially in some extremely severe patients. But we did not detect the significant correlation between severity of COVID-19 with IL-6 level which may be due to limited case numbers. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of COVID-19.

摘要

本单中心回顾性研究旨在探索 COVID-19 的免疫特征和预测疾病严重程度的生物标志物。纳入 2020 年 1 月 24 日至 3 月 12 日南昌大学第一附属医院收治的 215 例 SARS-CoV-2 感染患者,分为重症和非重症组。比较外周免疫细胞计数和细胞因子状态。分析免疫状态、细胞因子水平与疾病严重程度的相关性。两组白细胞计数均正常;然而,重症组白细胞计数相对较高(7.19×10/L)。两组白细胞分布不同;重症组中性粒细胞比例较高,淋巴细胞比例较低,两组绝对淋巴细胞计数均低于正常,重症组尤为明显。淋巴细胞计数与住院时间呈负相关,而中性粒细胞计数与住院时间无显著相关性。在检测的细胞因子中,重症组 IL-6 水平显著升高(P=0.0418)。淋巴细胞计数低预示 COVID-19 严重程度。重症组 IL-6 水平显著升高,尤其是部分极重症患者。但我们未检测到 COVID-19 严重程度与 IL-6 水平之间的显著相关性,这可能是由于病例数有限。我们的观察结果鼓励未来的研究以了解潜在的分子机制并改善 COVID-19 的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b32/7521864/6076f3f579a5/12026_2020_9156_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b32/7521864/6076f3f579a5/12026_2020_9156_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b32/7521864/6076f3f579a5/12026_2020_9156_Fig1_HTML.jpg

相似文献

1
Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2.免疫特征可区分与 SARS-CoV-2 相关的重症疾病患者。
Immunol Res. 2020 Dec;68(6):398-404. doi: 10.1007/s12026-020-09156-2. Epub 2020 Sep 28.
2
Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.利用 IL-2R/淋巴细胞预测 COVID-19 患者的临床进展。
Clin Exp Immunol. 2020 Jul;201(1):76-84. doi: 10.1111/cei.13450. Epub 2020 May 15.
3
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.SARS-CoV-2 感染患者外周血淋巴细胞反应和细胞因子谱的纵向特征。
EBioMedicine. 2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. Epub 2020 Apr 18.
4
IL-6-based mortality risk model for hospitalized patients with COVID-19.基于 IL-6 的 COVID-19 住院患者死亡风险模型。
J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9. doi: 10.1016/j.jaci.2020.07.009. Epub 2020 Jul 22.
5
Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.严重 COVID-19 诱导的急性呼吸窘迫综合征中的促炎和抗炎反应:一项观察性初步研究。
Front Immunol. 2020 Oct 6;11:581338. doi: 10.3389/fimmu.2020.581338. eCollection 2020.
6
Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.71 例 COVID-19 患者的临床特征和免疫损伤机制。
mSphere. 2020 Jul 15;5(4):e00362-20. doi: 10.1128/mSphere.00362-20.
7
Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019.HNC-LL 评分预测 2019 年冠状病毒病严重程度的开发和验证。
EBioMedicine. 2020 Jul;57:102880. doi: 10.1016/j.ebiom.2020.102880. Epub 2020 Jul 7.
8
Neutrophil-to-Lymphocyte Ratios Are Closely Associated With the Severity and Course of Non-mild COVID-19.中性粒细胞与淋巴细胞比值与非轻症 COVID-19 的严重程度和病程密切相关。
Front Immunol. 2020 Sep 2;11:2160. doi: 10.3389/fimmu.2020.02160. eCollection 2020.
9
Interleukin-6 and severity of COVID-19 patients in Hefei, China.中国合肥的白细胞介素 6 与 COVID-19 患者严重程度的关系。
Med Mal Infect. 2020 Oct;50(7):629-631. doi: 10.1016/j.medmal.2020.06.005. Epub 2020 Jun 25.
10
COVID-19 Is Distinct From SARS-CoV-2-Negative Community-Acquired Pneumonia.COVID-19 不同于 SARS-CoV-2 阴性社区获得性肺炎。
Front Cell Infect Microbiol. 2020 Jun 16;10:322. doi: 10.3389/fcimb.2020.00322. eCollection 2020.

引用本文的文献

1
Elevated Levels of Pleiotropic Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are Critically Involved With the Severity and Mortality of COVID-19: An Updated Longitudinal Meta-Analysis and Systematic Review on 147 Studies.多效性白细胞介素-6(IL-6)和白细胞介素-10(IL-10)水平升高与COVID-19的严重程度和死亡率密切相关:对147项研究的最新纵向荟萃分析和系统评价
Biomark Insights. 2022 Jun 16;17:11772719221106600. doi: 10.1177/11772719221106600. eCollection 2022.
2
T-Cell Subsets and Interleukin-10 Levels Are Predictors of Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis.T细胞亚群和白细胞介素-10水平是COVID-19严重程度和死亡率的预测指标:一项系统评价和荟萃分析
Front Med (Lausanne). 2022 Apr 28;9:852749. doi: 10.3389/fmed.2022.852749. eCollection 2022.
3

本文引用的文献

1
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
2
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
3
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情,该病毒可能来源于蝙蝠。
Innate Immune Response in SARS-CoV-2 Infection.新型冠状病毒感染中的固有免疫反应。
Microorganisms. 2022 Feb 23;10(3):501. doi: 10.3390/microorganisms10030501.
4
Differential blood leukocyte populations based on individual variances and age.基于个体差异和年龄的血液白细胞分类。
Immunol Res. 2022 Feb;70(1):114-128. doi: 10.1007/s12026-021-09257-6. Epub 2022 Jan 13.
5
In vitro induction of interleukin-8 by SARS-CoV-2 Spike protein is inhibited in bronchial epithelial IB3-1 cells by a miR-93-5p agomiR.SARS-CoV-2 刺突蛋白在支气管上皮 IB3-1 细胞中诱导白细胞介素-8 的体外诱导作用被 miR-93-5p 激动剂抑制。
Int Immunopharmacol. 2021 Dec;101(Pt B):108201. doi: 10.1016/j.intimp.2021.108201. Epub 2021 Sep 28.
6
Neutrophils at the crossroads of acute viral infections and severity.中性粒细胞在急性病毒感染和严重程度的十字路口。
Mol Aspects Med. 2021 Oct;81:100996. doi: 10.1016/j.mam.2021.100996. Epub 2021 Jul 18.
7
Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis.细胞因子风暴的生物标志物:严重和致命 COVID-19 病例的危险信号:一项实时系统评价和荟萃分析。
PLoS One. 2021 Jun 29;16(6):e0253894. doi: 10.1371/journal.pone.0253894. eCollection 2021.
8
Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.间充质干细胞联合外泌体作为 COVID-19 的新型细胞治疗方法:综述研究。
Clin Immunol. 2021 May;226:108712. doi: 10.1016/j.clim.2021.108712. Epub 2021 Mar 6.
9
Neutrophils and COVID-19: The road so far.中性粒细胞与2019冠状病毒病:迄今为止的进展
Int Immunopharmacol. 2021 Jan;90:107233. doi: 10.1016/j.intimp.2020.107233. Epub 2020 Nov 30.
10
Combined Interventions for Severe Novel Coronavirus Disease (COVID-19): Experience from 350 Patients.重症新型冠状病毒肺炎(COVID-19)的联合干预措施:350例患者的经验
Infect Drug Resist. 2020 Oct 30;13:3907-3918. doi: 10.2147/IDR.S279255. eCollection 2020.
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
4
Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.实时预测和预报源自中国武汉的 2019-nCoV 疫情在国内和国际的潜在传播:一项建模研究。
Lancet. 2020 Feb 29;395(10225):689-697. doi: 10.1016/S0140-6736(20)30260-9. Epub 2020 Jan 31.
5
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学:对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
6
Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.德国一名无症状接触者传播2019新型冠状病毒感染
N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30.
7
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.新型冠状病毒感染肺炎在中国武汉的早期传播动力学。
N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
8
Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam.越南新型冠状病毒的输入及人传人情况
N Engl J Med. 2020 Feb 27;382(9):872-874. doi: 10.1056/NEJMc2001272. Epub 2020 Jan 28.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.一个涉及 2019 年新型冠状病毒的家庭聚集性肺炎病例,提示存在人际传播:一项家庭聚集性研究。
Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.